Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920228 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
A Phase 2 study of Pachyonychia Congenita, sponsored by Palvella Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 9
- Study locations
NCT03920228: Completed Phase 2 study of Pachyonychia Congenita, sponsored by Palvella Therapeutics.
NCT03920228 is a Phase 2 study of Pachyonychia Congenita that has completed, run by Palvella Therapeutics. The registered enrollment target is 73 participants, below the 524-participant average among 4 other Pachyonychia Congenita trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03920228, a Phase 2 study of Pachyonychia Congenita, has completed, sponsored by Palvella Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PTX-022
Study Locations (9)
Arizona
- Arizona Research Center - Phoenix
California
- Stanford University - Palo Alto
Connecticut
- Yale University - New Haven
Florida
- International Dermatology Research - Miami
Illinois
- Northwestern University - Chicago
Minnesota
- Minnesota Clinical Study Center - Fridley
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Paddington Testing Co. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 2 |
What the finished NCT03920228 record still lists
NCT03920228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 524-participant average among 4 other Pachyonychia Congenita trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Pachyonychia Congenita appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03920228 lists 9 locations in 9 states (Arizona, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03920228 about?
NCT03920228 is a clinical study titled "Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita". This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
What is the current status of trial NCT03920228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2019-04-01. Estimated completion is 2020-10-19.
What conditions does trial NCT03920228 study?
This clinical trial studies the following conditions: Pachyonychia Congenita.
What interventions are being tested in trial NCT03920228?
The interventions under investigation include: Placebo (DRUG), PTX-022 (DRUG).
Who is sponsoring clinical trial NCT03920228?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03920228 being conducted?
This trial has 9 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pachyonychia Congenita
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
RECRUITING · Phase 3
-
International Pachyonychia Congenita Research Registry
RECRUITING
-
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
COMPLETED · Phase 1
-
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI